High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

被引:14
|
作者
Bischof, Katharina [1 ,2 ]
Knappskog, Stian [3 ,4 ]
Stefansson, Ingunn [5 ,6 ]
McCormack, Emmet Martin [1 ]
Trovik, Jone [2 ,7 ]
Werner, Henrica Maria Johanna [2 ,7 ]
Woie, Kathrine [2 ]
Gjertsen, Bjorn Tore [1 ,8 ]
Bjorge, Line [1 ,2 ]
机构
[1] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers CCBIO, Precis Oncol Res Grp, Bergen, Norway
[2] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway
[3] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway
[4] Univ Bergen, Sect Oncol, Dept Clin Sci, Bergen, Norway
[5] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway
[6] Univ Bergen, Sect Pathol, Dept Clin Med, CCBIO, Bergen, Norway
[7] Univ Bergen, Dept Clin Med, Bergen Gynaecol Canc Res Grp, Bergen, Norway
[8] Haukeland Hosp, Dept Internal Med, Haematol Sect, N-5021 Bergen, Norway
关键词
Uterine serous carcinoma; Type II endometrial cancer; p53; isoforms; RT-qPCR; mRNA expression analysis; Biomarker; INDEPENDENT PROGNOSTIC MARKER; CANCER; DELTA-133P53; P53-BETA; THERAPY; LESSONS; VARIANT; P73;
D O I
10.1186/s12885-018-4591-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding of its pathogenesis, and the p53 pathway has been proposed as a key player and is potentially targetable. Here we attempt to further portray the p53 pathway in USC by assessing p53 isoform expression. Methods: We applied quantitative Real-Time PCRs (RT-qPCR) for expression analyses of total p53 mRNA as well as quantitative distinction of p53 beta, p53 gamma, and the total mRNA of amino-terminal truncated Delta 40p53 and Delta 133p53 in a retrospective cohort of 37 patients with USC. TP53 mutation status was assessed by targeted massive parallel sequencing. Findings were correlated with clinical data. Results: The p53 isoform expression landscape in USCs was heterogeneous and dominated by total Delta 133p53, while the distinct p53 beta and p53 gamma variants were found at much lower levels. The isoform expression profiles varied between samples, while their expression was independent of TP53 mutation status. We found high relative p53 gamma expression to be associated with reduced progression-free survival (PFS). Conclusions: This is the first indication that elevated p53 gamma expression is associated with reduced PFS in USC. This singlecenter study may offer some insight in the landscape of p53 isoform expression in USC, but further validation studies are crucial to understand the context-dependent and tissue-specific role of the p53 isoform network in gynecological cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality
    Ito, R
    Nakayama, H
    Yoshida, K
    Oda, N
    Yasui, W
    ONCOLOGY REPORTS, 2004, 12 (05) : 985 - 990
  • [32] p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
    Tashiro, H
    Isacson, C
    Levine, R
    Kurman, RJ
    Cho, KR
    Hedrick, L
    AMERICAN JOURNAL OF PATHOLOGY, 1997, 150 (01): : 177 - 185
  • [33] p53 protein overexpression: A strong prognostic factor in uterine papillary serous carcinoma
    Bancher-Todesca, D
    Gitsch, G
    Williams, KE
    Kohlberger, P
    Neunteufel, W
    Obermair, A
    Heinze, G
    Breitenecker, G
    Hacker, NF
    GYNECOLOGIC ONCOLOGY, 1998, 71 (01) : 59 - 63
  • [34] p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma - Precursor of uterine papillary serous carcinoma
    Zheng, WX
    Khurana, R
    Farahmand, S
    Wang, YL
    Zhang, ZF
    Felix, JC
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) : 1463 - 1473
  • [35] PTEN Loss in High-Grade Serous Carcinomas is Associated with Reduced Expression of Hormonal Receptors and Poor Progression-Free Survival, and Mutually Exclusive with CCNE1 Amplification
    Zhang, Xiaoming
    Han, Lucy
    Liang, Brooke
    Wang, Aihui
    Howitt, Brooke
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 856 - 858
  • [36] PTEN Loss in High-Grade Serous Carcinomas is Associated with Reduced Expression of Hormonal Receptors and Poor Progression-Free Survival, and Mutually Exclusive with CCNE1 Amplification
    Zhang, Xiaoming
    Han, Lucy
    Liang, Brooke
    Wang, Aihui
    Howitt, Brooke
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 856 - 858
  • [37] Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients
    Troschel, Fabian M.
    Troschel, Benjamin O.
    Kloss, Maren
    Jost, Johanna
    Pepper, Niklas B.
    Voelk-Troschel, Amelie S.
    Wiewrodt, Rainer G.
    Stummer, Walter
    Wiewrodt, Dorothee
    Eich, Hans Theodor
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (09) : 774 - 784
  • [38] Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
    Furlong, Fiona
    Fitzpatrick, Patricia
    O'Toole, Sharon
    Phelan, Sine
    McGrogan, Barbara
    Maguire, Aoife
    O'Grady, Anthony
    Gallagher, Michael
    Prencipe, Maria
    McGoldrick, Aloysius
    McGettigan, Paul
    Brennan, Donal
    Sheils, Orla
    Martin, Cara
    Kay, Elaine W.
    O'Leary, John
    McCann, Amanda
    JOURNAL OF PATHOLOGY, 2012, 226 (05): : 746 - 755
  • [39] Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas
    Allard, Jay E.
    Risinger, John I.
    Morrison, Carl
    Young, Gregory
    Rose, G. Scott
    Fowler, Jeff
    Berchuck, Andrew
    Maxwell, G. Larry
    GYNECOLOGIC ONCOLOGY, 2007, 107 (01) : 52 - 57
  • [40] Correlation of p53 Immunohistochemical Expression with TP53 Mutation in Extrauterine High-Grade Serous Carcinoma
    Karim, Lina Abdul
    Yang, Richard
    Ramalingam, Preetha
    Lawson, Barrett
    Malpica, Anais
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 639 - 640